Oct 16, 2026 · 28 min · 11 segments
Dr. Matthew Sun interviews Dr. Ramona-Alexandra Todea and Dr. Riccardo Ludovichetti at University hospital Zurich about their paper recently published in Neuro-oncology advances, titled "Prediction of…
First of all, early progression is not destiny because molecular biology matters more than imaging timelines.
So don't abandon patients with early progression if they have favorable MGMT status.
And then I would also want to add something which is really very important.
So now I have the experience of working in two university hospitals.
And when you try to apply your thresholds in the perfusion studies from one study to the other center, I mean, between the two centers.
Even if I implemented the protocol exactly the same as I had it in my previous affiliation, my thresholds, they are different.
So for this reason, I would really commend my colleagues that I think this should be a standard of care that everyone who is using perfusion studies should run at least a small retrospective study to see which are their thresholds in their department.
And once you know what are your thresholds and with what you're dealing with, then you can start doing all your research in the following years or months.
So this would be the first indication to do institution-specific studies.
And then, as our study has shown, it is very important to add always new molecular prognostic markers, a reason why I think that our neuro-oncology boards are very important in keeping A good relationship with the pathologist and neuro-oncologist helps you to keep a pace with the emerging molecular prognostic markers, but also with the evolving therapeutic options.
I think it has to be really interconnected to give the best for our patients.
It's all going to help our patients remove some of the uncertainty and also ease a lot of the anxiety that we have.
First of all, early progression is not destiny because molecular biology matters more than imaging timelines.
So don't abandon patients with early progression if they have favorable MGMT status.
And then I would also want to add something which is really very important.
So now I have the experience of working in two university hospitals.
And when you try to apply your thresholds in the perfusion studies from one study to the other center, I mean, between the two centers.
Even if I implemented the protocol exactly the same as I had it in my previous affiliation, my thresholds, they are different.
So for this reason, I would really commend my colleagues that I think this should be a standard of care that everyone who is using perfusion studies should run at least a small retrospective study to see which are their thresholds in their department.
And once you know what are your thresholds and with what you're dealing with, then you can start doing all your research in the following years or months.
So this would be the first indication to do institution-specific studies.
And then, as our study has shown, it is very important to add always new molecular prognostic markers, a reason why I think that our neuro-oncology boards are very important in keeping A good relationship with the pathologist and neuro-oncologist helps you to keep a pace with the emerging molecular prognostic markers, but also with the evolving therapeutic options.
I think it has to be really interconnected to give the best for our patients.
It's all going to help our patients remove some of the uncertainty and also ease a lot of the anxiety that we have.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
